![logo](/logos/IMTX.webp)
Immatics N.V.
NASDAQ:IMTX
11.73 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Immatics N.V. |
Symbool | IMTX |
Munteenheid | USD |
Prijs | 11.73 |
Beurswaarde | 1,208,811,690 |
Dividendpercentage | 0% |
52-weken bereik | 7.15 - 13.77 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Harpreet Singh Ph.D. |
Website | https://www.immatics.com |
An error occurred while fetching data.
Over Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)